Nouscom AG: Abstract on interim results from Phase 1 trial for NOUS-209, an “off-the-shelf” neoantigen cancer vaccine, in MSI-H solid tumors will be presented at SITC
Our abstract “Phase 1 Interim Study Results of Nous-209, an Off-the-Shelf Immunotherapy, with Pembrolizumab, for the Treatment of Tumors with a Deficiency in Mismatch Repair/ Microsatellite Instability (dMMR/MSI-H)” will be presented by Dr Dung Le, MD, The John Hopkins University, a Senior Investigator of the trial, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (November 10-14, 2021). Dr. Michael J. Overman, MD, Anderson Cancer Center, Principal Investigator of the trial provided the narration (e-poster presentation).
Poster presentation details:
- Poster number: 410
- Date: November 13, 2021
- Time: 12:30-14:00 and 19:00-20:30 EST
- Location: Poster Hall, Walter E. Washington Convention Center, Washington, D.C.
For more information: https://www.sitcancer.org/home